IFI-M · CBK Tri-Axis Dominant-Primary Series

Specimen SS-F-M3-02283 // MULTI-AXIS · IFI-M

CBK Tri-Axis Dominant-Primary Series II-PR

Mentha × piperita

Peppermint

Tier IICBK Tri-Axis Dominant-Primary Series

Target Trait

1.52×

fold-change

Cooling-dominant tri-axis B+K modulated fold-change

Technical Specifications

SKU

SS-F-M3-02283

Genomic Edits

8

GC Content

47.1%

Construct Length

5,091 bp

Promoter System

Ubiquitin / T7

Expression System

Protoplast PEG-fusion

Host Strain

PEG-mediated

Receptor Target

TRPM8 + TAS2R38 (suppression) + CaSR

IFI Score

152

Pathway Edits

  • TRPM8 pathway primary gene cluster for cooling (IFI-C) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • CaSR pathway primary gene cluster for kokumi (IFI-K) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent CBK pathway operation
  • Cross-pathway regulatory circuit for cooling-dominant CBK triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: TRPM8, TAS2R38 (suppression), and CaSR pathways simultaneously engineeredCooling-dominant tri-axis expression strategy (CBK) with cross-pathway flux managementPEG-mediated co-transfection of axis constructs for rapid phenotypic screening of multi-axis combinations

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier II CBK triple-axis construct for advanced multi-modal sensory architecture combining cooling, bitter-attenuation, and kokumi axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$699 · Tier II License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?